Pharmaceutical

FDA issues CRL to Orexo’s NDA for opioid overdose medication

The US FDA has issued a complete response letter (CRL) to Orexo regarding its NDA for OX124 to counteract opioid overdoses.

Jul 18, 2024 - 04:00
FDA issues CRL to Orexo’s NDA for opioid overdose medication
The US FDA has issued a complete response letter (CRL) to Orexo regarding its NDA for OX124 to counteract opioid overdoses.
Read the original article

Tags:

Previous Article

China NMPA approves Zai Lab-argenx’s efgartigimod alfa for gMG

Next Article

Autoimmune-Stricken Patients Respond to Allogeneic CAR-T Treatment

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: A breakthrough cystic fibrosis drug gave them the gift of time. But miracles come with complications.

STAT+: A breakthrough cystic fibrosis drug gave them th...

Sep 20, 2023

STAT+: Judge skeptical of arguments against Medicare drug price negotiation

STAT+: Judge skeptical of arguments against Medicare dr...

Feb 1, 2024

STAT+: Pharmalittle: Weight-loss drugs fuel boom for firms that fill syringes; employers that cover obesity drug may double in 2024

STAT+: Pharmalittle: Weight-loss drugs fuel boom for fi...

Oct 10, 2023